191 related articles for article (PubMed ID: 32323889)
1. Antitumor Activity of Larotrectinib in Esophageal Carcinoma with NTRK Gene Amplification.
Hempel D; Wieland T; Solfrank B; Grossmann V; Steinhard J; Frick A; Hempel L; Eberl T; Gaumann A
Oncologist; 2020 Jun; 25(6):e881-e886. PubMed ID: 32323889
[TBL] [Abstract][Full Text] [Related]
2. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.
Hong DS; Bauer TM; Lee JJ; Dowlati A; Brose MS; Farago AF; Taylor M; Shaw AT; Montez S; Meric-Bernstam F; Smith S; Tuch BB; Ebata K; Cruickshank S; Cox MC; Burris HA; Doebele RC
Ann Oncol; 2019 Feb; 30(2):325-331. PubMed ID: 30624546
[TBL] [Abstract][Full Text] [Related]
3. A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report.
Zhang L; Liu H; Tian Y; Wang H; Yang X
BMC Pulm Med; 2021 Apr; 21(1):125. PubMed ID: 33865348
[TBL] [Abstract][Full Text] [Related]
4. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
5. TRK Inhibitors: Clinical Development of Larotrectinib.
Bhangoo MS; Sigal D
Curr Oncol Rep; 2019 Feb; 21(2):14. PubMed ID: 30715603
[TBL] [Abstract][Full Text] [Related]
6. Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib.
Awada A; Berghmans T; Clement PM; Cuppens K; De Wilde B; Machiels JP; Pauwels P; Peeters M; Rottey S; Van Cutsem E
Crit Rev Oncol Hematol; 2022 Jan; 169():103564. PubMed ID: 34861380
[TBL] [Abstract][Full Text] [Related]
7. Larotrectinib: A Targeted Therapy for Solid Tumors.
Mota-George G; Schneider SM
Clin J Oncol Nurs; 2021 Apr; 25(2):181-187. PubMed ID: 33739345
[TBL] [Abstract][Full Text] [Related]
8. Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion.
Filippi R; Depetris I; Satolli MA
Expert Opin Pharmacother; 2021 Apr; 22(6):677-684. PubMed ID: 33576301
[No Abstract] [Full Text] [Related]
9. From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis.
Cui Z; Zhai Z; Xie D; Wang L; Cheng F; Lou S; Zou F; Pan R; Chang S; Yao H; She J; Zhang Y; Yang X
Front Pharmacol; 2024; 15():1329409. PubMed ID: 38357305
[No Abstract] [Full Text] [Related]
10. Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.
Fuse MJ; Okada K; Oh-Hara T; Ogura H; Fujita N; Katayama R
Mol Cancer Ther; 2017 Oct; 16(10):2130-2143. PubMed ID: 28751539
[No Abstract] [Full Text] [Related]
11. Transforming approaches to treating TRK fusion cancer: historical comparison of larotrectinib and histology-specific therapies.
Pollack M; Keating K; Wissinger E; Jackson L; Sarnes E; Cuffel B
Curr Med Res Opin; 2021 Jan; 37(1):59-70. PubMed ID: 33148054
[TBL] [Abstract][Full Text] [Related]
12. Primary Resistance to Larotrectinib in a Patient With Squamous NSCLC With Subclonal
Boulanger MC; Temel JS; Mino-Kenudson M; Ritterhouse LL; Dagogo-Jack I
JTO Clin Res Rep; 2023 Apr; 4(4):100501. PubMed ID: 37095749
[TBL] [Abstract][Full Text] [Related]
13. Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.
Farago AF; Demetri GD
Future Oncol; 2020 Mar; 16(9):417-425. PubMed ID: 32129093
[TBL] [Abstract][Full Text] [Related]
14. Case Report: Adult NTRK-Rearranged Spindle Cell Neoplasm: Early Tumor Shrinkage in a Case With Bone and Visceral Metastases Treated With Targeted Therapy.
Recine F; De Vita A; Fausti V; Pieri F; Bongiovanni A; Franchini E; Casadei R; Falasconi MC; Oboldi D; Matteucci F; Pallotti MC; Mercatali L; Riva N; Gurrieri L; Vanni S; Liverani C; Miserocchi G; Spadazzi C; Cocchi C; Ibrahim T
Front Oncol; 2021; 11():740676. PubMed ID: 35070960
[TBL] [Abstract][Full Text] [Related]
15. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
Federman N; McDermott R
Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968
[No Abstract] [Full Text] [Related]
16. Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors.
Sigal DS; Bhangoo MS; Hermel JA; Pavlick DC; Frampton G; Miller VA; Ross JS; Ali SM
Oncotarget; 2018 Nov; 9(88):35809-35812. PubMed ID: 30533196
[TBL] [Abstract][Full Text] [Related]
17. [NTRK Fusions: A new way of treatment for gastro-intestinal tumor?].
Ouali K; Pellat A; Cohen R; Svrcek M; Penault-Llorca F; André T
Bull Cancer; 2020 Apr; 107(4):447-457. PubMed ID: 32067719
[TBL] [Abstract][Full Text] [Related]
18. Larotrectinib (LOXO-101).
Berger S; Martens UM; Bochum S
Recent Results Cancer Res; 2018; 211():141-151. PubMed ID: 30069765
[TBL] [Abstract][Full Text] [Related]
19. Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers.
Boilève A; Verlingue L; Hollebecque A; Boige V; Ducreux M; Malka D
Expert Opin Investig Drugs; 2021 Apr; 30(4):401-409. PubMed ID: 33641556
[No Abstract] [Full Text] [Related]
20. Redifferentiating Effect of Larotrectinib in
Groussin L; Theodon H; Bessiene L; Bricaire L; Bonnet-Serrano F; Cochand-Priollet B; Leroy K; Garinet S; Pasmant E; Zerbit J; Seban R; Goldwasser F; Clerc J; Cottereau AS; Huillard O
Thyroid; 2022 May; 32(5):594-598. PubMed ID: 35171708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
